Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19

Area of Science:

• Immunology
• Regenerative Medicine
• Virology

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, leading to severe pneumonia, ARDS, and organ dysfunction.
• No specific treatments are currently proven effective for COVID-19.
• Mesenchymal stromal/stem cells (MSCs) demonstrate safety and efficacy in treating respiratory viral infections via differentiation and immunomodulation.

Purpose of the Study:

• To review the characteristics and mechanisms of COVID-19 and MSCs.
• To outline preclinical and clinical studies of MSCs and MSC-derived extracellular vesicles (EVs) for respiratory virus infections.
• To discuss challenges and safety concerns for translating MSC therapy into clinical practice.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of MSC and MSC-EV mechanisms in viral infections.
• Discussion of translational challenges and safety considerations.

Main Results:

• MSCs and MSC-EVs exhibit therapeutic potential for respiratory viral infections, including influenza and SARS-CoV-2.
• MSC-EVs offer advantages over MSCs for therapeutic applications.
• Key challenges and safety issues in MSC therapy require further investigation.

Conclusions:

• MSC-based therapies, including MSC-derived EVs, hold significant potential for treating COVID-19 and other respiratory viral infections.
• Overcoming translational hurdles and addressing safety concerns are crucial for clinical implementation.
• Further research is warranted to optimize MSC and MSC-EV therapies for respiratory viral diseases.